Search
Enter keywords, a title or a report id number below.
Central Nervous System
-
- -
- - You are in Central Nervous System category
- - You are in Central Nervous System category
- -
In 2012 major changes might revolutionize the treatment of multiple sclerosis, as Gilenya, the first novel drug in five years, will be joined by three new products: BG-12, Aubagio, and Lemtrada. Recent exciting developments in drug discovery might also enhance the hopes of those fighting against Alzheimer.
Great commercial and scientific opportunities are to be found in similar battles against a range of diseases and neurodegenerative disorders, e.g. Parkinson’s disease, schizophrenia,
... more
Sort by
Sorted by
Date Published
-
Perception Journal
Pion Ltd, May 2013Perception is a scholarly journal reporting experimental results and theoretical ideas ranging over the fields of human, animal, and machine perception Topics covered include physiological mechanisms... -
Neuroscience Media Monitor
Moreover Technologies, May 2013About the service: When neuroscience news breaks, we get it fast—so you can deliver fresh business intelligence - Search 33,500 news sources - Plus, search 508,000 social media sources - Covers 200... -
Neurological Research
Maney Publishing, May 201310 issues per year Neurological Research is an international, peer-reviewed journal for reporting both basic and clinical research in the fields of neurosurgery, neurology, neuroengineering and neurosciences... -
Nutritional Neuroscience
Maney Publishing, May 2013"6 issues per year (Online Only) Nutritional Neuroscience is an international, interdisciplinary broad-based journal for reporting both basic and clinical research in the field of nutrition that relates... -
Neurotech Business Report
Neurotech Reports, May 2013Neurotech Business Report is the first publication targeting the business of neurotechnology, the application of engineering techniques to human neural and information processing systems Each monthly... -
Alzheimer Disease - New Drugs, Markets and Companies
Jain PharmaBiotech, May 2013 , Pages: 550Alzheimer's disease remains a challenge in management With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future Considerable... -
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
Jain PharmaBiotech, May 2013 , Pages: 355The delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders Drugs may be administered directly into the CNS or administered systematically (e g ,... -
Disruptive Behavior Disorder - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 154Disruptive Behavior Disorder – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Disruptive Behavior Disorder - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic... -
Essential Tremor - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 32Essential Tremor – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Essential Tremor - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report... -
Paralysis - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 38Paralysis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Paralysis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information... -
Sedation - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 48Sedation – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Sedation - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information... -
Muscle Spasticity - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 28Muscle Spasticity – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Muscle Spasticity - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report... -
Cerebral Palsy - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 51Cerebral Palsy – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Cerebral Palsy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides... -
Neuropathy - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 77Neuropathy – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Neuropathy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides... -
Motor Neurone Diseases - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 37Motor Neurone Diseases – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Motor Neurone Diseases - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline.... -
Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 56Relapsing Multiple Sclerosis (RMS) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2013', provides an overview of the indication’s... -
Acute Spinal Cord Injury - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 58Acute Spinal Cord Injury – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Acute Spinal Cord Injury - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline.... -
Delirium Global Clinical Trials Review, H1, 2013
GlobalData, Apr 2013 , Pages: 83Delirium Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Delirium Global Clinical Trials Review, H1, 2013" provides data on the Delirium clinical trial scenario. This report... -
Dyskinesia Global Clinical Trials Review, H1, 2013
GlobalData, Apr 2013 , Pages: 136Dyskinesia Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Dyskinesia Global Clinical Trials Review, H1, 2013" provides data on the Dyskinesia clinical trial scenario.... -
Dystonia Global Clinical Trials Review, H1, 2013
GlobalData, Apr 2013 , Pages: 134Dystonia Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Dystonia Global Clinical Trials Review, H1, 2013" provides data on the Dystonia clinical trial scenario. This report... -
Radiculopathy Global Clinical Trials Review, H1, 2013
GlobalData, Apr 2013 , Pages: 100Radiculopathy Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Radiculopathy Global Clinical Trials Review, H1, 2013" provides data on the Radiculopathy clinical trial scenario.... -
Anorexia Nervosa Global Clinical Trials Review, H1, 2013
GlobalData, Apr 2013 , Pages: 81Anorexia Nervosa Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Anorexia Nervosa Global Clinical Trials Review, H1, 2013" provides data on the Anorexia Nervosa clinical... -
Anesthetic Effect - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 62Anesthetic Effect – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Anesthetic Effect - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report... -
Friedreich Ataxia - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 62Friedreich Ataxia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Friedreich Ataxia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report... -
Memory Impairment - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 50Memory Impairment – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Memory Impairment - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report... -
Partial Seizure - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 112Partial Seizure – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Partial Seizure - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report... -
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 63Post-Traumatic Stress Disorder (PTSD) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2013', provides an overview of the indication’s... -
Psychiatric Disorders - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 409Psychiatric Disorders – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Psychiatric Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline.... -
Ischemic Stroke - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 187Ischemic Stroke – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Ischemic Stroke - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report... -
Dyslexia Global Clinical Trials Review, H1, 2013
GlobalData, Apr 2013 , Pages: 59Dyslexia Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Dyslexia Global Clinical Trials Review, H1, 2013" provides data on the Dyslexia clinical trial scenario. This report... -
Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2013
GlobalData, Apr 2013 , Pages: 79Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2013" provides data on the Lennox-Gastaut... -
Tardive Dyskinesia Global Clinical Trials Review, H1, 2013
GlobalData, Apr 2013 , Pages: 83Tardive Dyskinesia Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Tardive Dyskinesia Global Clinical Trials Review, H1, 2013" provides data on the Tardive Dyskinesia clinical... -
Traumatic Brain Injury - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 161Traumatic Brain Injury – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Traumatic Brain Injury - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline.... -
Alcohol Addiction - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 88Alcohol Addiction – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Alcohol Addiction - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report... -
Mild Cognitive Impairment - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 91Mild Cognitive Impairment – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Mild Cognitive Impairment - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline.... -
Chronic Pain - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 270Chronic Pain – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Chronic Pain - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides... -
Depression - Pipeline Review, H1 2013
Global Markets Direct, Apr 2013 , Pages: 518Depression – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Depression - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides... -
Global Bipolar Disorder Pipeline Capsule - 2013
Commercial Insights, Apr 2013 , Pages: 25Fore Pharma’s latest report ‘Global Bipolar Disorder Pipeline Capsule – 2013’ provides up-to-date information on key Research and Development (R&D) activities in the global bipolar disorder market.... -
Analyzing the Global CNS Market
Aruvian's R'search, Apr 2013 , Pages: 200The CNS market at a global scale is one of the largest and fastest growing markets in the pharmaceutical industry. Reimbursement terms remain favorable within the area, despite the relatively high risks... -
PharmaPoint: Multiple Sclerosis - Current and Future Players
GlobalData, Mar 2013 , Pages: 55“PharmaPoint: Multiple Sclerosis - Current and Future Players” The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Multiple Sclerosis... -
Fatigue Global Clinical Trials Review, H1, 2013
GlobalData, Mar 2013 , Pages: 116Fatigue Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Fatigue Global Clinical Trials Review, H1, 2013" provides data on the Fatigue clinical trial scenario. This report... -
PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022
GlobalData, Mar 2013 , Pages: 158“PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022” Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination,... -
Aubagio (Multiple Sclerosis) - Forecast and Market Analysis to 2022
GlobalData, Mar 2013 , Pages: 61PharmaPoint Drug Evaluation report, “Aubagio (Multiple Sclerosis) - Forecast and Market Analysis to 2022” Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically... -
Gilenya (Multiple Sclerosis) - Forecast and Market Analysis to 2022
GlobalData, Mar 2013 , Pages: 48“Gilenya (Multiple Sclerosis) - Forecast and Market Analysis to 2022” Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection... -
Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H1, 2013
GlobalData, Mar 2013 , Pages: 175Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review,... -
BG-12 (Multiple Sclerosis) - Forecast and Market Analysis to 2022
GlobalData, Mar 2013 , Pages: 62BG-12 (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “BG-12 (Multiple Sclerosis) - Forecast and Market Analysis... -
Masitinib (Multiple Sclerosis) - Forecast and Market Analysis to 2022
GlobalData, Mar 2013 , Pages: 60Masitinib (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Masitinib (Multiple Sclerosis) - Forecast and Market... -
Ocrelizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022
GlobalData, Mar 2013 , Pages: 61Ocrelizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Ocrelizumab (Multiple Sclerosis) - Forecast and... -
PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022
GlobalData, Mar 2013 , Pages: 155PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis - Germany Drug Forecast... -
Avonex (Multiple Sclerosis) - Forecast and Market Analysis to 2022
GlobalData, Mar 2013 , Pages: 48Avonex (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Avonex (Multiple Sclerosis) - Forecast and Market Analysis...
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
